Clinical Trials Browser

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06504940 2026-02-27

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Phase 2 Recruiting

69 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Phase 2 Recruiting

49 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06350318 2026-02-05

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Phase 2 Recruiting

43 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07372365 2026-01-28

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

Phase 2 Recruiting

23 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06647732 2026-01-15

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Phase 2 Recruiting

42 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04792502 2025-12-30

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Phase 2 Recruiting

52 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT06986174 2025-12-05

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Phase 2 Recruiting

30 enrolled

Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06390956 2025-12-04

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Phase 2 Recruiting

23 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Phase 2 Recruiting

27 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

40 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06796998 2025-10-28

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Phase 2 Recruiting

25 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07208981 2025-10-06

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Phase 2 Recruiting

169 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05296070 2025-09-30

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

50 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Recruiting

25 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2 Recruiting

65 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Phase 2 Recruiting

56 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Phase 2 Recruiting

300 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT06700798 2025-06-17

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Phase 2 Recruiting

90 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07022223 2025-06-15

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Phase 2 Recruiting

51 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05734495 2025-05-11

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Phase 2 Recruiting

42 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05281809 2025-01-13

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Phase 2 Recruiting

30 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06566807 2024-08-22